← FDA DRUG APPROVALS

FDA ANDA · ANDA209333

SOLIFENACIN SUCCINATE

Sponsor: QILU

APPLICATION
ANDA209333
TYPE
ANDA
ORIGINAL APPROVAL
2019-05-20
LATEST ACTION
2021-03-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SOLIFENACIN SUCCINATEPrescription
SOLIFENACIN SUCCINATE 10MG · TABLET · ORAL
SOLIFENACIN SUCCINATEPrescription
SOLIFENACIN SUCCINATE 5MG · TABLET · ORAL

Approval history

2021-03-17Labeling · Supplement 1 · standardAP
2019-05-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →